Editorial: Rethinking infection in pediatric atopic dermatitis: from microbial dysbiosis to precision prevention - Report - MDSpire

Editorial: Rethinking infection in pediatric atopic dermatitis: from microbial dysbiosis to precision prevention

  • By

  • Hui Gan

  • Oksana Boyarchuk

  • Aiping Feng

  • Lingyu Jiang

  • Kun Yang

  • June 24, 2026

  • 0 min

Share

Clinical Report: Reevaluating Infection in Pediatric Atopic Dermatitis

Background

Atopic dermatitis is a prevalent chronic skin condition affecting 15-20% of children worldwide, characterized by skin barrier defects and immune dysregulation. The interplay between microbial imbalance and AD exacerbates susceptibility to infections.

Data Highlights

No numerical data available in the source material.

Key Findings

  • Infection in pediatric AD is a dynamic, multifactorial process rather than a mere consequence of eczema.
  • Children with AD and molluscum contagiosum require more treatment sessions compared to those without AD.
  • AD is linked to unique microbial profiles and increased difficulty in clearing infections.
  • Comorbid conditions, such as autism spectrum disorder, can influence the immune response in children with AD.
  • Genetic factors contribute to the severity and early onset of AD.

Clinical Implications

Healthcare providers should focus on comprehensive management of atopic dermatitis.

Conclusion

The insights gathered emphasize the need for a holistic approach to managing pediatric atopic dermatitis.

Related Resources & Content

  1. Lomelí-Valdez et al., Frontiers in Immunology, 2026 -- Reevaluating Infection in Pediatric Atopic Dermatitis
  2. Li et al., Frontiers in Pediatrics, 2026 -- The therapeutic potential of natural products for pediatric psoriasis
  3. Abidov and Bayer, Frontiers in Immunology, 2026 -- Restoring balance in atopic disorders
  4. AAD Issues Pediatric Atopic Dermatitis Guidelines, conexiant, 2026
  5. Atopic dermatitis clinical guideline, American Academy of Dermatology, 2026
  6. The Safety Data of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis, American Journal of Clinical Dermatology, 2025
  7. Correlation between Staphylococcus aureus colonization and disease severity in atopic dermatitis, Frontiers in Immunology, 2026
  8. Atopic dermatitis clinical guideline
  9. The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults | American Journal of Clinical Dermatology | Springer Nature Link
  10. Frontiers | Correlation between Staphylococcus aureus colonization and disease severity in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials

Original Source(s)

Related Content